2022_Oct_PDA_Universe_CA_leaderboard

Ophthalmic Drug Delivery94

Issue No #94 January 14th, 2019

Inside the magazine

USING MARKET RESEARCH TO CREATE A PRESERVATIVE-FREE MULTIDOSE EYEDROPPER

Silgan Dispensing

USING MARKET RESEARCH TO CREATE A PRESERVATIVE-FREE MULTIDOSE EYEDROPPER

Thomas Grinnan and Ralf Hergenröther explain how extensive market research and consumer testing led to the development of an eyedropper that meets patients’ and physicians’ needs for an easy-to-use device, which offers precise dosing and anti-microbial integrity.

USER TESTING: CRITICAL FOR TRULY UNDERSTANDING PATIENT NEEDS

USER TESTING: CRITICAL FOR TRULY UNDERSTANDING PATIENT NEEDS

Fanny Sellier presents a trio of comparative user studies between Nemera’s Novelia^® preservative-free, multidose eyedropper and similar products from competitors

ACCURATE, PRECISE MICROLITRE DOSING WITH PREFILLABLE SYRINGES FOR OPHTHALMIC INJECTIONS

Dr Gautam N Shetty

Congruence Medical Solutions

ACCURATE, PRECISE MICROLITRE DOSING WITH PREFILLABLE SYRINGES FOR OPHTHALMIC INJECTIONS

Gautam Shetty discusses the challenges inherent to delivering microlitre dosage volumes accurately from a standard prefilled syringe, and introduces Congruence’s Microlitre Dosing Syringe (MDS) platform as a solution.

BREAKING THE VICIOUS CIRCLE OF DRY EYE DISEASE

Dr Christian Roesky

BREAKING THE VICIOUS CIRCLE OF DRY EYE DISEASE

Christian Roesky discusses the underserved condition of dry eye disease, and presents two products in Novaliq’s pipelinefor the treatment of different types of DED.

KEEPING PRESERVATIVE-FREE EYEDROPS STERILE WITH THE STERIDROP™ TUBE

Hoffmann Neopac

KEEPING PRESERVATIVE-FREE EYEDROPS STERILE WITH THE STERIDROP™ TUBE

Ralf Künzi introduces the SteriDrop™ tube – a new multidose eyedrop delivery solution made in collaboration with Aptar Pharma.

THE CHALLENGES AND OPPORTUNITIES OF DRUG DELIVERY THROUGH A COMPLEX BARRIER

THE CHALLENGES AND OPPORTUNITIES OF DRUG DELIVERY THROUGH A COMPLEX BARRIER

Jon Volmer, Marc Brown and Jeremy Drummond discuss the development and use of advanced ex vivo and in vitro models for testing new ocular medicines to meet a growing unmet need.

TARGETING DRUGS TO DISEASED OCULAR CELLS

Frazer P Coutinho

TARGETING DRUGS TO DISEASED OCULAR CELLS

Frazer Coutinho, Colin Green and Ilva Rupenthal discuss the targeted delivery of ocular therapeutics to diseased cells, using the cell-penetrating peptide, Xentry.

INTRAVITREAL INJECTION OF VEGF INHIBITORS – IMPACT OF DRUG CONTAINERS

INTRAVITREAL INJECTION OF VEGF INHIBITORS – IMPACT OF DRUG CONTAINERS

With the increasing use of intravitreal injections of vascular endothelial growth factor inhibitors in the treatment of numerous serious ocular diseases, Douglas Cusato provides a detailed comparative analysis of the issues at play.

ACUSTREAM™: BRINGING TOPICAL OPHTHALMIC DRUG DELIVERY INTO THE MODERN ERA

Dr Peter Noymer

Kedalion Therapeutics

ACUSTREAM™: BRINGING TOPICAL OPHTHALMIC DRUG DELIVERY INTO THE MODERN ERA

Peter Noymer, Ehud Ivri, Reynaldo Quintana and Mark Blumenkranz introduce AcuStream, a novel device for next-generation delivery of topical ophthalmic delivery via an aim-assisted stream.

TRENDS IN ANTI-GLAUCOMA TOPICAL TREATMENTS

TRENDS IN ANTI-GLAUCOMA TOPICAL TREATMENTS

Rouven Kraus presents the case for multidose delivery systems rather than single-use disposables, and introduces Aero Pump’s Ophthalmic Multidose System.

Top